Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax

Sara Zarnegar-Lumley, Seth E. Karol, Stanley Pounds, Jeffery M. Klco, Maria Luisa Sulis, Dennis John Kuo, Kenneth Matthew Heym, Kathleen Ludwig, Alexandra McLean Stevens, Thomas B. Alexander, Kelly Elizabeth Faulk, Himalee S. Sabnis, Sarah K. Tasian, Jeffrey Taub, Andrew E. Place, Jeffrey E. Rubnitz

Blood (2023) 142 (Supplement 1): 56.

https://doi.org/10.1182/blood-2023-174342

Published: 2023

Journal Articles

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Blood (2022) 140 (Supplement 1): 7763–7765.

https://doi.org/10.1182/blood-2022-160272

Published: 2022

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Jesús Gutiérrez-Abril, Daniel Leongamornlert, Neerav N Shukla, Maria Luisa Sulis, Yangyu Zhou, Max F. Levine, Emilio Barretta, SooWah Lee, Juan E. Arango-Ossa, Gunes Gundem, Juan S. Medina-Martínez, Bela Patel Wrench, Anthony V. Moorman, Adele K. Fielding, Andrew L. Kung, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 1197–1199.

https://doi.org/10.1182/blood-2022-160322

Published: 2022

Journal Articles

Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2021-151837

Published: 2021

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

Journal Articles

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Uma H. Athale, MD, M.Sc., Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Menachem Spira, Peter D. Cole, MD, Barbara L Asselin, MD, Luis A. Clavell, MD, Kara M. Kelly, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 1278.

https://doi.org/10.1182/blood.V130.Suppl_1.1278.1278

Published: 2017

Journal Articles

Clonal Evolution Mechanisms and Collateral Sensitivity to Impdh Inhibitor Therapy in Relapsed Lymphoblastic Leukemia

Chelsea Dieck, Gannie Tzoneva, PhD, Koichi Oshima, MD PhD, Alberto Ambesi-Impiombato, Marta Sanchez-Martin, PhD, Maria Luisa Sulis, MD, Motohiro Kato, MD PhD, Katsuyoshi Koh, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD, Julie M. Gastier-Foster, PhD, Mignon L. Loh, MD, Renate Kirschner-Schwabe, PhD, Chioma Madubata, Raul Rabadan, Adolfo A. Ferrando, MD PhD

Blood (2017) 130 (Supplement 1): 2602.

https://doi.org/10.1182/blood.V130.Suppl_1.2602.2602

Published: 2017

Journal Articles

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Kara M. Kelly, MD, Elena Ladas, PhD, Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Meiko Lin, MA, Peter D Cole, MD, Manuela Orjuela, MD ScM, Uma Athale, Luis A. Clavell, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Barbara L Asselin, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 2549.

https://doi.org/10.1182/blood.V130.Suppl_1.2549.2549

Published: 2017

Journal Articles

Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 4068.

https://doi.org/10.1182/blood.V128.22.4068.4068

Published: 2016

Journal Articles

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Blood (2016) 128 (22): 175.

https://doi.org/10.1182/blood.V128.22.175.175

Published: 2016

Journal Articles

Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia

Lianna J Marks, MD, Jennifer A Oberg, EdD, Julia L Glade-Bender, MD, Susan J Hsiao, MD, Danielle Pendrick, MPH, Anthony N Sireci, MD, Stuart J Andrews, PhD, Mahesh M Mansukhani, MD, Andrew L. Kung, MD PhD, Maria Luisa Sulis, MD

Blood (2016) 128 (22): 5250.

https://doi.org/10.1182/blood.V128.22.5250.5250

Published: 2016

Journal Articles

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Uma H. Athale, MD, M.Sc., Maneka Puligandla, MS, Kristen E. Stevenson, MS, Barbara L. Asselin, MD, Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2016) 128 (22): 761.

https://doi.org/10.1182/blood.V128.22.761.761

Published: 2016

Journal Articles

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Maria Luisa Sulis, MD, Traci M. Blonquist, MS, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Donna S Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 249.

https://doi.org/10.1182/blood.V126.23.249.249

Published: 2015

Journal Articles

Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia

Andrew E. Place, MDPhD, Yana Pikman, MD, Kristen Stevenson, MS, Marian H. Harris, MD PhD, Todd M. Cooper, DO, Lia Gore, MD, Nobuko Hijiya, MD, Mignon L. Loh, MD, Melinda Pauly, MD, Maria Luisa Sulis, MD, Donna S Neuberg, ScD, Kimberly Stegmaier, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 3765.

https://doi.org/10.1182/blood.V126.23.3765.3765

Published: 2015

Journal Articles

Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Lia Gore, MD, Richard Sposto, PhD, Deepa Bhojwani, Bill H Chang, MD PhD, Steven G. Dubois, MD, Paul S Gaynon, MD, Julia Glade-Bender, MD, Kenneth Matthew Heym, MD, Maria Luisa Sulis, MD, Jessica A. Pollard, MD, Anupam Verma, MD, Van Huynh, MD

Blood (2014) 124 (21): 3650.

https://doi.org/10.1182/blood.V124.21.3650.3650

Published: 2014

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

Journal Articles

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 471.

https://doi.org/10.1182/blood.V116.21.471.471

Published: 2010

NARROW

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Clonal Evolution Mechanisms and Collateral Sensitivity to Impdh Inhibitor Therapy in Relapsed Lymphoblastic Leukemia

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia

Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only